Basic Information
AMMTeK is a French biotechnology company developing products for the treatment of neonatal diabetes. The company’s proprietary patented liquid product, Amglidia, was approved by the EMA in 2018. The product has been granted orphan drug designation in the United States.
AMMTeK
Paris,Ile-de-France,France
unclear
--
--
contact@ammtek.eu
Enterprise Profile
Industrial Sector
Concept
Application Scenarios